Assess Efficacy and Safety of TachoComb H vs. Standard Surgical Treatment (i.e. Suturing) in Patients Undergoing Prostatectomy (TC-017-AU)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

120 participants

Study Classification

INTERVENTIONAL

Study Start Date

2004-05-31

Study Completion Date

2007-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The overall objective is to compare efficacy and safety of TachoComb H versus standard surgical treatment for the control of local bleeding in patients undergoing prostatectomy. Specific objectives include the comparison between test treatments for intraoperative haemostatic efficacy as well as for post-operative blood loss to be assessed by haemoglobin and haematocrit concentration of drainage fluid.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Trial of Modifications to Radical Prostatectomy

NCT01407263

Prostate Cancer

ACTIVE_NOT_RECRUITING PHASE3

Prevention of Post Operative Urinary Retention After Thoracic Surgery Trial

NCT06262048

Urinary Retention Postoperative

RECRUITING PHASE2

Prophylactic Tamsulosin Use for Prevention of Post-Operative Urinary Retention

NCT02684344

Post-Operative Urinary Retention

TERMINATED NA

EFFICACY of INTRAOPERATIVE ARISTA POLYSACCHARIDE APPLICATION on the POSTOPERATIVE BLOOD LOSS in PATIENTS UNDERGOING RARP for the TREATMENT of PROSTATE CANCER

NCT06822036

Prostate Cancer (Adenocarcinoma) Blood Loss, Postoperative Erectile Function

RECRUITING NA

Pre-operative Tamsulosin and Time to Spontaneous Void After Hysterectomy

NCT04859660

Urinary Retention Postoperative

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Control of Local Bleeding in Patients Undergoing Prostatectomy.

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Human fibrinogen/thrombin and bovine aprotinin (TachoComb H)

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. has the subject given informed consent according to local requirements before any trial related activies? A trial related activity is any procedure that would not have been performed during the routine management of the subject.
2. Is the subject 18 years of age or above ?
3. Is the subject planned for a radical prostatectomy for prostate cancer (cT3)?

After prostate resection and primary haemostatic treatment
4. is only minor (i.e. oozing) or moderate haemorrhage persisting after primary surgical haemostatic procedures of the major vessels (no pulsating arterial haemorrhage and/or major venous bleeding)?

Exclusion:

At pre-operative screen

1. Is there anamnestic or laboratory evidence of coagulation disorders including haemophilia A or B and von Willebrand disease ?
2. Has the patient a history of allergic reactions after application of human fibrinogen, human thrombin, bovine aprotinin and/or collagen of any origin?
3. Is the patient undergoing an emergency operation?
4. Did the patient participate in a clinical trial less than 30 days prior to inclusion in present trial?
5. Does the patient participate in a clinical trial concomitantly with present trial?

After tumour resection and primary haemostatic treatment
6. Has any serious surgical complication occurred?
7. Has any fibrin glue haemostatic (including any type of TachoComb) been used before randomisation?

Minimum Eligible Age

18 Years

Maximum Eligible Age

90 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No